The post Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights appeared on BitcoinEthereumNews.com. Rebeca Moen Nov 03, 2025 04:19 Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE. Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle. Advancing Precision Medicine The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery. Empowering Clinicians and Patients Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible. Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery. Strategic Objectives and Benefits The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include: Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being. Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s… The post Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights appeared on BitcoinEthereumNews.com. Rebeca Moen Nov 03, 2025 04:19 Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE. Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle. Advancing Precision Medicine The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery. Empowering Clinicians and Patients Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible. Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery. Strategic Objectives and Benefits The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include: Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being. Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s…

Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights

2025/11/04 12:26


Rebeca Moen
Nov 03, 2025 04:19

Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE.

Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle.

Advancing Precision Medicine

The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery.

Empowering Clinicians and Patients

Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible.

Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery.

Strategic Objectives and Benefits

The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include:

  • Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being.
  • Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s leadership in personalized healthcare.
  • Nationwide Access: Developing a secure, scalable patient portal for seamless access to health records, enhancing care coordination and patient engagement.

Enhancing Treatment Efficacy

Seema Verma, Executive Vice President at Oracle Health and Life Sciences, highlighted the role of pharmacogenomic insights in delivering more personalized care. By tailoring medications to a patient’s genetic profile, the initiative aims to enhance treatment efficacy, improve preventive care, and reduce the waste associated with ineffective prescriptions. This aligns with the UAE’s vision of pioneering health innovation and delivering exceptional, patient-centric care.

The Emirati Genome Program, one of the world’s largest genomic initiatives, plays a crucial role in this endeavor by advancing disease prevention and enabling early diagnosis and personalized treatments based on local genetic profiles.

Image source: Shutterstock

Source: https://blockchain.news/news/oracle-m42-collaborate-enhance-healthcare-genomic-insights

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin ETFs Record Strongest Inflows Since July, Push Holdings to New High

Bitcoin ETFs Record Strongest Inflows Since July, Push Holdings to New High

The post Bitcoin ETFs Record Strongest Inflows Since July, Push Holdings to New High appeared on BitcoinEthereumNews.com. In brief Bitcoin ETPs saw a net inflow of 20,685 BTC last week, driven mostly by U.S. ETFs. The recent uptick in investor risk appetite is driven by rate cut expectations and new crypto IPOs. Despite institutional demand outpacing new Bitcoin supply, realized and implied volatility remain historically low. Bitcoin exchange-traded products globally logged net inflows of 20,685 BTC last week, the strongest weekly intake since July 22, according to digital assets firm K33 Research. The renewed momentum lifted U.S. spot bitcoin ETFs’ combined holdings to 1.32 million BTC, surpassing the previous peak set on July 30. U.S. Bitcoin ETF products contributed nearly 97% of last week’s 20,685 BTC ETP inflows, highlighting the surge in demand ahead of the FOMC meeting.  Bitcoin ETF inflows “tend to be one of the key determinants of Bitcoin’s performance,” André Dragosch, head of research for Europe at Bitwise Investments, told Decrypt, adding that the “percentage share of Bitcoin’s performance explained by changes in ETP flows” has reached a new all-time high. Compared with Ethereum ETF flows, “there appears to be a ‘re-rotation’ from Ethereum back to Bitcoin in terms of investor flows,” Dragosch said, citing their data. “Over the past week, flows into Bitcoin ETFs have surpassed new supply growth by a factor of 8.93 times, a key tailwind for Bitcoin’s recent performance.”  Analysts at K33 agree, writing that flows have been a key driver of bitcoin’s strength since ETF approvals earlier last year, and the latest surge signals an acceleration in demand that could underpin further price support. In the last 30 days, investors accumulated roughly 22,853 BTC via various products, outpacing the new supply of 14,056 BTC. This rising risk appetite for Bitcoin has supported the recent recovery, Bitwise noted in its Monday report. Fidelity’s FBTC product accounted for a substantial…
Share
BitcoinEthereumNews2025/09/18 10:19